Related Articles
Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN
Palbociclib added to ongoing endocrine therapy for hormone receptor‑positive HER2‑negative metastatic breast cancer: A case report series
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells
Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs